Vinod Surabhi S, Reed Annelle B, Maxwell Jamelle, Cron Randy Q, Stoll Matthew L
Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA.
Division of Pediatric Rheumatology, Children's of Alabama, Birmingham, AL, 35233-1711, USA.
Pediatr Rheumatol Online J. 2018 Mar 9;16(1):16. doi: 10.1186/s12969-018-0234-0.
Children with chronic rheumatic disease often require intravenous (IV) therapy. Our center has instituted standardized protocols for use of IV medications in rheumatology patients. Herein, we introduce the therapeutic protocols and report on their short-term safety.
This was an institutional review board (IRB) approved retrospective chart review of all patients who had received IV infusions between the years 2012 and 2015 at a single center, prescribed by a pediatric rheumatologist. Infusion medications included abatacept, belimumab, cyclophosphamide, immune globulin, infliximab, methylprednisolone, N-acetylcysteine, pamidronate disodium, rituximab, and tocilizumab. For calendar year 2015, all adverse infusions reactions were recorded along with treatment strategies used to manage them, and outcomes. Rates of adverse events were calculated per infusion medication.
During calendar years 2012-2015, 7585 IV infusions were administered to 398 unique patients. In the year 2015, 2187 infusions were administered to 224 patients, with 34 patients experiencing 41 infusion reactions (1.9% of all infusions). Rituximab had the highest rate of adverse drug reactions with 10 patients experiencing reactions during 106 infusions (9.4%). None of the reactions were life-threatening, and only 6 resulted in discontinuation of therapy.
In a recent 4-year span, the UAB Pediatric Rheumatology Infusion Center has given thousands of IV infusions with minimal adverse reactions over a one-year reporting period. The combination of standard infusion protocols, experience of and communication between physicians and nurses who staff the center, and safety of the medications themselves, allows for safe IV administration of a variety of therapies for pediatric rheumatology patients.
Not applicable; this was a retrospective study.
患有慢性风湿性疾病的儿童常常需要静脉注射（IV）治疗。我们中心已经制定了在风湿病患者中使用静脉注射药物的标准化方案。在此，我们介绍治疗方案并报告其短期安全性。
这是一项经机构审查委员会（IRB）批准的回顾性病历审查，审查对象为2012年至2015年间在单一中心由儿科风湿病学家开处方接受静脉输注的所有患者。输注药物包括阿巴西普、贝利木单抗、环磷酰胺、免疫球蛋白、英夫利昔单抗、甲泼尼龙、N-乙酰半胱氨酸、帕米膦酸二钠、利妥昔单抗和托珠单抗。对于2015日历年，记录了所有不良输注反应以及用于处理这些反应的治疗策略和结果。计算每种输注药物的不良事件发生率。
在2012 - 2015日历年期间，对398名独特患者进行了7585次静脉输注。2015年，对224名患者进行了2187次输注，其中34名患者出现41次输注反应（占所有输注的1.9%）。利妥昔单抗的药物不良反应发生率最高，106次输注中有10名患者出现反应（9.4%）。所有反应均无生命危险，只有6次导致治疗中断。
在最近4年的时间里，阿拉巴马大学伯明翰分校儿科风湿病输注中心在一年的报告期内进行了数千次静脉输注，不良反应极少。标准输注方案、中心医护人员（医生和护士）的经验及沟通以及药物本身的安全性相结合，使得为儿科风湿病患者安全静脉给药各种治疗成为可能。
不适用；这是一项回顾性研究。
